EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial

Marinde J G Bond iD, Karen Bolhuis, Martinus J van Amerongen, Thiery Chapelle, Ronald M van Dam, Marc R W Engelbrecht, Michael F Gerhards, Dirk J Grünhagen iD, Thomas van Gulik, John J Hermans, Koert P de Jong, Geert Kazemier und 14 weitere

BJS Open · 2025

DOI: 10.1093/bjsopen/zraf125 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift BJS Open, 2025. Verfasst von Marinde J G Bond und 25 weiteren Autor:innen. Beteiligte Einrichtung: Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hepatectomy, Liver Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Considerable variability exists among liver surgeons in assessing resectability and local treatment planning of initially unresectable colorectal cancer liver-only metastases (CRLM). This study analysed short-term and survival outcomes of one-stage versus two-stage surgery for CRLM.

Methods

Patients with initially unresectable CRLM were included from the phase 3 CAIRO5 study. In patients in whom both one-stage and two-stage approaches were suggested by individual panel surgeons, these approaches were compared. The study population includes only patients for whom both approaches were discussed by the panel surgeons. Overall survival curves were estimated with the Kaplan–Meier method and compared with the two-sided stratified log-rank test. Other surgical and postoperative outcomes were compared using a two-sample t test and Pearson’s χ2 test or Fisher’s exact test, as appropriate.

Results

Local surgeons planned one-stage versus two-stage surgery in 53 versus 51 patients, respectively. In the one-stage versus two-stage surgery groups, the median age was 59 (interquartile range (i.q.r.) 52–69) versus 59 (i.q.r. 53–68) years, respectively, and the median number of CRLM was 9 (i.q.r. 6.5–13) versus 10 (i.q.r. 7.5–14), respectively. Median overall survival was 46.5 versus 34.0 months (HR 0.61; 95% confidence interval 0.38 to 0.99; P = 0.043) with planned one-stage versus two-stage surgery, respectively. In one-stage versus two-stage surgery, Clavien–Dindo grade ≥ 3 complications occurred in 11 versus 13 patients (P = 0.567), portal vein embolization was performed in 2 versus 41 patients (P < 0.001), and local treatment was complete (R0/R1 resection or ablation of all CRLM) in 52 versus 29 patients (P < 0.001), respectively. Major liver resection was performed in 19 versus 28 patients with complete planned one-stage versus two-stage surgery, respectively, with a corresponding 32 versus 12 patients undergoing ablation.

Conclusion

One-stage surgery with/without ablation appears to be the optimal treatment approach for patients with initially unresectable CRLM for whom both one- and two-stage approaches are considered. Nonetheless, two-stage surgery remains vital for complex CRLM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHepatectomyLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedKaplan-Meier EstimateTreatment Outcome

Stichwörter der Autor:innen

bilobarfuture liver remnantliver resectionportal vein embolisation

Autor:innen und Institutionen

  • Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Radiology, Sint Maartenskliniek, Nijmegen, the Netherlands.
  • Department of Hepatobiliary, Transplantation, and Endocrine Surgery, Antwerp University Hospital, Antwerp, Belgium.
  • Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, the Netherlands.

ORCID-Profile: Marinde J G Bond, Dirk J Grünhagen, Cornelis Verhoef, Johannes H W de Wilt, Rutger-Jan Swijnenburg

Förderung

  • Roche
  • Amgen

Zitieren

APA

Bond, M. J. G., Bolhuis, K., van Amerongen, M. J., Chapelle, T., van Dam, R. M., Engelbrecht, M. R. W., Gerhards, M. F., Grünhagen, D. J., van Gulik, T., Hermans, J. J., de Jong, K. P., Kazemier, G., Klaase, J. M., Kok, N. F. M., Leclercq, W. K. G., Liem, M. S. L., van Lienden, K. P., Molenaar, I. Q., Patijn, G. A., …, & Swijnenburg, R. J. (2025). One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial. BJS Open. https://doi.org/10.1093/bjsopen/zraf125

Vancouver

Bond MJG, Bolhuis K, van Amerongen MJ, Chapelle T, van Dam RM, Engelbrecht MRW, et al. One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial. BJS Open. 2025. doi:10.1093/bjsopen/zraf125

BibTeX
@article{Bond2025,
  author = {Bond, Marinde J G and Bolhuis, Karen and van Amerongen, Martinus J and Chapelle, Thiery and van Dam, Ronald M and Engelbrecht, Marc R W and Gerhards, Michael F and Grünhagen, Dirk J and van Gulik, Thomas and Hermans, John J and de Jong, Koert P and Kazemier, Geert and Klaase, Joost M and Kok, Niels F M and Leclercq, Wouter K G and Liem, Mike S L and van Lienden, Krijn P and Molenaar, I Quintus and Patijn, Gijs A and Rijken, Arjen M and Ruers, Theo M and Verhoef, Cornelis and de Wilt, Johannes H W and May, Anne M and Punt, Cornelis J A and Swijnenburg, Rutger-Jan},
  title = {One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial},
  journal = {BJS Open},
  year = {2025},
  doi = {10.1093/bjsopen/zraf125}
}
Kostenlos starten →